Article
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
British journal of haematology - 1 Oct 2016
Bhatnagar Bhavana, Eisfeld Ann-Kathrin, Nicolet Deedra, Mrózek Krzysztof, Blachly James S, Orwick Shelley, Lucas David M, Kohlschmidt Jessica, Blum William, Kolitz Jonathan E, Stone Richard M, Bloomfield Clara D, Byrd John C
Abstract excerpt
Somatic mutation of the DNMT3A gene at the arginine R882 site is common in acute myeloid leukaemia (AML). The prognostic significance of DNMT3A R882 mutation clearance, using traditional diagnostic next generation sequencing (NGS) methods, during complete remission (CR) in AML patients is controversial. We examined the impact of clearing DNMT3A R882 mutations at diagnosis to the detectable threshold of ˂3% during...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.